Soligenix Shares Decline Following $7.5M Public Offering Announcement to Raise Funds
Public Offering Announcement: Soligenix has priced a public offering of 5,555,560 shares of common stock and accompanying warrants at $1.35 per unit, aiming to raise approximately $7.5 million in gross proceeds.
Use of Proceeds and Warrant Details: The funds will be used for research, development, and general corporate purposes, while the new warrants will have an exercise price of $1.35, be immediately exercisable, and expire in five years.
Trade with 70% Backtested Accuracy
Analyst Views on SNGX
About SNGX
About the author
Soligenix Outlines Strategic Vision for 2026
- Market Potential Assessment: Soligenix anticipates that annual net sales of HyBryte™ in the U.S. will exceed $90 million, with the total addressable worldwide CTCL market estimated at over $250 million, indicating strong market demand and potential returns.
- Robust Financing Strategy: As of September 30, 2025, Soligenix reported approximately $10.5 million in cash, along with $500,000 in non-dilutive funding, ensuring the company can meet its development goals through 2026, thereby boosting investor confidence.
- Clinical Trial Progress: The company is advancing its confirmatory Phase 3 clinical trial for HyBryte™, with multiple significant milestones expected in 2026, which will pave the way for future market authorizations and enhance its competitive position.
- Strategic Partnership Opportunities: Soligenix is evaluating partnerships in international markets, aiming to accelerate the global marketing authorization process for HyBryte™ through collaborations with companies that have similar reputations and expertise, further expanding its business footprint.
Soligenix Provides Update on Clinical Trials and Strategic Options
- Clinical Trial Progress: As of February 10, 2026, Soligenix has enrolled 66 patients in the Phase 3 FLASH2 clinical trial for HyBryte™, with top-line results expected in the second half of 2026, enhancing confidence in the interim analysis and potentially boosting the company's competitiveness in the cutaneous T-cell lymphoma market.
- Treatment Success Rate: In an open-label study, 75% of early-stage CTCL patients achieved 'Treatment Success' after 18 weeks of HyBryte™ treatment, indicating the therapy's potential in chronic cancer treatment and laying a foundation for future market promotion.
- Market Opportunity Assessment: Peak annual sales of HyBryte™ in the U.S. are expected to exceed $90 million, with the total addressable worldwide CTCL market estimated at over $250 million, highlighting the company's commercial potential in the rare disease sector.
- Financing Strategy: With approximately $10.5 million in cash reported as of September 30, 2025, Soligenix is well-positioned to meet its funding needs for advancing development programs in 2026, demonstrating ongoing investment and growth potential in rare disease therapeutics.
Soligenix Publishes Positive Phase 2a Results for SGX945 in Behçet's Disease Treatment
- Clinical Trial Results: Soligenix's SGX945 demonstrated significant improvement in 7 out of 8 patients in a Phase 2a trial for Behçet's Disease, indicating potential enduring effects after 4 weeks of treatment, which could enhance patient quality of life.
- Efficacy Comparison: After 4 weeks, the SGX945 group showed a 40% improvement relative to placebo, comparable to the 37% improvement seen with the approved drug apremilast, suggesting SGX945's competitive edge in the market.
- Patient Feedback: Patients reported reduced duration and number of oral ulcers during treatment, with SGX945 showing no treatment-related adverse events, indicating strong tolerability and potential for broader patient adoption.
- Future Development Plans: Soligenix intends to reformulate SGX945 for home-based treatment via subcutaneous injection, aiming to expand its application in innate immune-related inflammatory conditions, thereby enhancing its market competitiveness.
Soligenix Expands Psoriasis Trial, Revealing Improved Results with New Gel
Trial Results: Soligenix, Inc. announced extended results from its Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, showing improvements in various clinical measures with a new gel formulation that enhances application ease.
Patient Tolerance: The SGX302 gel therapy was well tolerated by all patients, with no drug-related adverse events reported, and one patient achieved a significant improvement in their psoriasis status.
Comparative Outcomes: The results from the gel formulation were comparable to or improved upon those from the previous ointment formulation, indicating effective treatment potential for psoriasis lesions.
Stock Performance: Following the announcement, Soligenix's stock experienced a decline of 21.05%, trading at $1.21.
Soligenix Reports Clinical Success of Optimized SGX302 Gel for Psoriasis Treatment
- Trial Expansion: Soligenix has enrolled four additional patients in its Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, utilizing an optimized gel formulation over an 18-week treatment period, with all patients well tolerated and no drug-related adverse events reported.
- Efficacy Assessment: Among the three evaluable patients, the average PASI score improved by over 50%, with one patient achieving an “Almost Clear” disease status, indicating that the new formulation shows comparable or improved efficacy relative to the previous ointment formulation.
- Market Potential: With an estimated 60-125 million psoriasis patients globally and a treatment market valued at approximately $15 billion in 2020, projected to reach $40 billion by 2027, the success of SGX302 could present significant market opportunities for the company.
- Future Directions: Soligenix plans to continue advancing SGX302 for psoriasis while preparing for the confirmatory Phase 3 trial of HyBryte™ in early-stage cutaneous T-cell lymphoma, with topline results expected in the second half of 2026.
Soligenix Reaches Enrollment Target for Interim Analysis in Phase 3 Clinical Trial of HyBryte™ for Cutaneous T-Cell Lymphoma Treatment
Study Enrollment and Interim Analysis: Soligenix, Inc. has completed the enrollment of 50 patients in its Phase 3 FLASH 2 study evaluating HyBryte™ for cutaneous T-cell lymphoma (CTCL), with an interim analysis expected in Q2 2026. The study aims to confirm the efficacy of HyBryte™, building on previous successful trials.
Response Rates and Safety Profile: The overall blinded study response rate to date is 48%, significantly exceeding the anticipated 25%. The safety profile of HyBryte™ remains benign, consistent with earlier studies, and is expected to demonstrate efficacy over an extended treatment period.
Mechanism of Action and Treatment Approach: HyBryte™ utilizes synthetic hypericin activated by visible light, offering a safer alternative to traditional therapies that carry risks of DNA damage and secondary malignancies. This treatment approach targets malignant T-cells while minimizing systemic absorption.
Regulatory Path and Future Prospects: Following the first Phase 3 study, regulatory bodies require a second successful trial for marketing approval. Soligenix is in discussions with the FDA regarding study design modifications, while also pursuing additional studies to support HyBryte™'s efficacy and safety in treating CTCL.
Soligenix Outlines Strategic Vision for 2026
- Market Potential Assessment: Soligenix anticipates that annual net sales of HyBryte™ in the U.S. will exceed $90 million, with the total addressable worldwide CTCL market estimated at over $250 million, indicating strong market demand and potential returns.
- Robust Financing Strategy: As of September 30, 2025, Soligenix reported approximately $10.5 million in cash, along with $500,000 in non-dilutive funding, ensuring the company can meet its development goals through 2026, thereby boosting investor confidence.
- Clinical Trial Progress: The company is advancing its confirmatory Phase 3 clinical trial for HyBryte™, with multiple significant milestones expected in 2026, which will pave the way for future market authorizations and enhance its competitive position.
- Strategic Partnership Opportunities: Soligenix is evaluating partnerships in international markets, aiming to accelerate the global marketing authorization process for HyBryte™ through collaborations with companies that have similar reputations and expertise, further expanding its business footprint.
Soligenix Provides Update on Clinical Trials and Strategic Options
- Clinical Trial Progress: As of February 10, 2026, Soligenix has enrolled 66 patients in the Phase 3 FLASH2 clinical trial for HyBryte™, with top-line results expected in the second half of 2026, enhancing confidence in the interim analysis and potentially boosting the company's competitiveness in the cutaneous T-cell lymphoma market.
- Treatment Success Rate: In an open-label study, 75% of early-stage CTCL patients achieved 'Treatment Success' after 18 weeks of HyBryte™ treatment, indicating the therapy's potential in chronic cancer treatment and laying a foundation for future market promotion.
- Market Opportunity Assessment: Peak annual sales of HyBryte™ in the U.S. are expected to exceed $90 million, with the total addressable worldwide CTCL market estimated at over $250 million, highlighting the company's commercial potential in the rare disease sector.
- Financing Strategy: With approximately $10.5 million in cash reported as of September 30, 2025, Soligenix is well-positioned to meet its funding needs for advancing development programs in 2026, demonstrating ongoing investment and growth potential in rare disease therapeutics.
Soligenix Publishes Positive Phase 2a Results for SGX945 in Behçet's Disease Treatment
- Clinical Trial Results: Soligenix's SGX945 demonstrated significant improvement in 7 out of 8 patients in a Phase 2a trial for Behçet's Disease, indicating potential enduring effects after 4 weeks of treatment, which could enhance patient quality of life.
- Efficacy Comparison: After 4 weeks, the SGX945 group showed a 40% improvement relative to placebo, comparable to the 37% improvement seen with the approved drug apremilast, suggesting SGX945's competitive edge in the market.
- Patient Feedback: Patients reported reduced duration and number of oral ulcers during treatment, with SGX945 showing no treatment-related adverse events, indicating strong tolerability and potential for broader patient adoption.
- Future Development Plans: Soligenix intends to reformulate SGX945 for home-based treatment via subcutaneous injection, aiming to expand its application in innate immune-related inflammatory conditions, thereby enhancing its market competitiveness.
Soligenix Expands Psoriasis Trial, Revealing Improved Results with New Gel
Trial Results: Soligenix, Inc. announced extended results from its Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, showing improvements in various clinical measures with a new gel formulation that enhances application ease.
Patient Tolerance: The SGX302 gel therapy was well tolerated by all patients, with no drug-related adverse events reported, and one patient achieved a significant improvement in their psoriasis status.
Comparative Outcomes: The results from the gel formulation were comparable to or improved upon those from the previous ointment formulation, indicating effective treatment potential for psoriasis lesions.
Stock Performance: Following the announcement, Soligenix's stock experienced a decline of 21.05%, trading at $1.21.
Soligenix Reports Clinical Success of Optimized SGX302 Gel for Psoriasis Treatment
- Trial Expansion: Soligenix has enrolled four additional patients in its Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, utilizing an optimized gel formulation over an 18-week treatment period, with all patients well tolerated and no drug-related adverse events reported.
- Efficacy Assessment: Among the three evaluable patients, the average PASI score improved by over 50%, with one patient achieving an “Almost Clear” disease status, indicating that the new formulation shows comparable or improved efficacy relative to the previous ointment formulation.
- Market Potential: With an estimated 60-125 million psoriasis patients globally and a treatment market valued at approximately $15 billion in 2020, projected to reach $40 billion by 2027, the success of SGX302 could present significant market opportunities for the company.
- Future Directions: Soligenix plans to continue advancing SGX302 for psoriasis while preparing for the confirmatory Phase 3 trial of HyBryte™ in early-stage cutaneous T-cell lymphoma, with topline results expected in the second half of 2026.
Soligenix Reaches Enrollment Target for Interim Analysis in Phase 3 Clinical Trial of HyBryte™ for Cutaneous T-Cell Lymphoma Treatment
Study Enrollment and Interim Analysis: Soligenix, Inc. has completed the enrollment of 50 patients in its Phase 3 FLASH 2 study evaluating HyBryte™ for cutaneous T-cell lymphoma (CTCL), with an interim analysis expected in Q2 2026. The study aims to confirm the efficacy of HyBryte™, building on previous successful trials.
Response Rates and Safety Profile: The overall blinded study response rate to date is 48%, significantly exceeding the anticipated 25%. The safety profile of HyBryte™ remains benign, consistent with earlier studies, and is expected to demonstrate efficacy over an extended treatment period.
Mechanism of Action and Treatment Approach: HyBryte™ utilizes synthetic hypericin activated by visible light, offering a safer alternative to traditional therapies that carry risks of DNA damage and secondary malignancies. This treatment approach targets malignant T-cells while minimizing systemic absorption.
Regulatory Path and Future Prospects: Following the first Phase 3 study, regulatory bodies require a second successful trial for marketing approval. Soligenix is in discussions with the FDA regarding study design modifications, while also pursuing additional studies to support HyBryte™'s efficacy and safety in treating CTCL.
